Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines
- PMID: 10875259
- DOI: 10.1210/endo.141.7.7546
Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines
Abstract
Expression of MET, the receptor for hepatocyte growth factor (HGF), has been associated with androgen-insensitive prostate cancer. In this study we evaluated MET activation by HGF and HGF action in prostate cancer cell lines. HGF causes phosphorylation (activation) of the MET receptor in three androgen-unresponsive cell lines (DU 145, PC-3, and ALVA-31) together with morphological change. Although HGF is known to stimulate the growth of normal epithelial cells, including those from prostate, we found that HGF inhibited ALVA-31 and DU 145 (hormone-refractory) cell lines. Moreover, HGF and vitamin D additively inhibited growth in each androgen-unresponsive cell line, with the greatest growth inhibition in ALVA-31 cells. Further studies in ALVA-31 cells revealed distinct cooperative actions of HGF and vitamin D. In contrast to the accumulation of cells in G1 seen during vitamin D inhibition of androgen-responsive cells (LNCaP), growth inhibition of the androgen-unresponsive ALVA-31 cell line with the HGF and vitamin D combination decreased, rather than increased, the fraction of cells in G1, with a corresponding increase in the later cell cycle phases. This cell cycle redistribution suggests that in androgen-unresponsive prostate cancer cells, HGF and vitamin D act together to slow cell cycle progression via control at sites beyond the G1/S checkpoint, the major regulatory locus of growth control in androgen-sensitive prostate cells.
Similar articles
-
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.Am J Pathol. 1995 Aug;147(2):386-96. Am J Pathol. 1995. PMID: 7639332 Free PMC article.
-
Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.Mol Cell Endocrinol. 2002 Jan 15;186(1):69-79. doi: 10.1016/s0303-7207(01)00671-2. Mol Cell Endocrinol. 2002. PMID: 11850123
-
Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation.Endocrinology. 1998 Mar;139(3):1197-207. doi: 10.1210/endo.139.3.5770. Endocrinology. 1998. PMID: 9492054
-
Prostate cancer and the met hepatocyte growth factor receptor.Adv Cancer Res. 2004;91:31-67. doi: 10.1016/S0065-230X(04)91002-0. Adv Cancer Res. 2004. PMID: 15327888 Review.
-
Vitamin D in Prostate Cancer.Vitam Horm. 2016;100:321-55. doi: 10.1016/bs.vh.2015.10.012. Epub 2015 Dec 8. Vitam Horm. 2016. PMID: 26827958 Review.
Cited by
-
The MET Family of Receptor Tyrosine Kinases Promotes a Shift to Pro-Tumor Metabolism.Genes (Basel). 2024 Jul 20;15(7):953. doi: 10.3390/genes15070953. Genes (Basel). 2024. PMID: 39062731 Free PMC article. Review.
-
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor.Am J Pathol. 2001 Aug;159(2):579-90. doi: 10.1016/S0002-9440(10)61729-4. Am J Pathol. 2001. PMID: 11485916 Free PMC article.
-
Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone.Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):189-199. eCollection 2018. Am J Nucl Med Mol Imaging. 2018. PMID: 30042870 Free PMC article.
-
Interaction of vitamin D with membrane-based signaling pathways.Front Physiol. 2014 Feb 18;5:60. doi: 10.3389/fphys.2014.00060. eCollection 2014. Front Physiol. 2014. PMID: 24600406 Free PMC article. Review.
-
SF/HGF-c-Met autocrine and paracrine promote metastasis of hepatocellular carcinoma.World J Gastroenterol. 2001 Dec;7(6):816-20. doi: 10.3748/wjg.v7.i6.816. World J Gastroenterol. 2001. PMID: 11854908 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous